Kangxian ruangan keli inhibits hepatic stellate cell proliferation mediated by PDGF

Table 1 Effects of KXR on PDGF-mediated HSC proliferation (mean ± s)

Groups	KXR concentration (mg/mL)	OD values	Inhibitory rate (%)
Control		0.17 ± 0.06b	-
PDGF		0.82 ± 0.05	0.00
KXR treatment before	5	0.28 ± 0.03b	65.9
PDGF stimulation	2.5	0.37 ± 0.02b	54.9
	1.25	0.43 ± 0.04b	47.6

^bP < 0.01 vs PDGF group.

Table 2 Effect of KXR on cell cycle progression of HSCs mediated by PDGF (mean ± s)

Groups	n	HSC fractions at (%)
		G0-G1 phase	S phase	G2-M phase
Control	6	94.67 ± 2.17	4.13 ± 0.92	1.20 ± 0.47
PDGF 10 ng/mL	6	20.18 ± 1.12	68.24 ± 2.72	11.18 ± 1.93
KXR 5 mg/mL→PDGF	6	83.64 ± 3.68b	10.95 ± 1.35b	5.41 ± 0.98b
KXR 2.5 mg/mL→PDGF	6	62.58 ± 4.52b	32.76 ± 1.07b	4.66 ± 0.81b
KXR 1.25 mg/mL→PDGF	6	48.18 ± 3.37b	43.19 ± 1.09b	8.63 ± 0.71a

^aP < 0.05,

^bP < 0.01 vs PDGF group.

Table 3 Effect of KXR on the contents of tyrosine-phosphorylated proteins in HSCs stimulated by PDGF (mean ± s)

Groups	n	Intensities of tyrosine-phosphorylated proteins
Control	4	0.1199 ± 0.0037
PDGF 10 mg/mL	4	0.1813 ± 0.0117
KXR 1.25 mg/mL+PDGF	4	0.1658 ± 0.0025a
KXR 5 mg/mL+PDGF	4	0.1349 ± 0.0072b

^aP < 0.05,

^bP < 0.01 vs PDGF group.